10
DNA of Biopreneur A.S.Rao Adviser-Innovation Clusters,FMC [email protected] http://www.indiainvents.blogspo t.com/

Dna of biopreneur

Embed Size (px)

DESCRIPTION

Waht

Citation preview

Page 1: Dna of biopreneur

DNA of Biopreneur

A.S.RaoAdviser-Innovation Clusters,FMC

[email protected]://www.indiainvents.blogspot.com/

Page 2: Dna of biopreneur

Molecule millionaires

• Scientist turned promoter: Dr Anji Reddy (DPR), Ketan R Patel(Troikka), Krishna Ella (Bharat Biotech), Ramanbhai Patel(Cadia),

• Biopreneurs: Ranbir Singh & Gurbax Singh (Ranbaxy), UN Mehta (Torrent), Varaprasad Reddy (Shanta Biotech), Raghavendra rao (Orchid)

Page 3: Dna of biopreneur

Signature of success

• Master the virtuous cycle of knowledge management.

• Identify business opportunity, decipher key factors, relate to technology, acquire technology and raise the stock of Firm Specific Knowledge.

• Learn to network with knowledge partners and knowledge workers.

• Lead cluster formation as network orchestrator

Page 4: Dna of biopreneur

Knowledge cycle

Business opportunity

Technology driver

Access knowledge

Acquire knowledge

Assimilate knowledge

Leverage knowledge

Take knowledge dividend

Start next cycle

Page 5: Dna of biopreneur

Opportunities

• Patents not enforced in India• Drugs going off the patents• Affordable health care• 100 global technologies shortlisted by

knowledge partner Sky Quest.

Page 6: Dna of biopreneur

Patents not enforced in India

• http://www.globalinnovationcommons.org

• Buruli Ulcer, Dengue Fever, Dracunculiasis (Guinea Worm Disease), Leprosy, Lymphatic Filariasis, Malaria, Sickle Cell Anemia, Snake Bite, Spider Bite

Page 7: Dna of biopreneur

Going off the patent

• 22 drugs will go off-patent in India by 2015-Rituxan, an anti-neoplastic mAbs from Roche; Lantus, an antidiabetics from Sanofi aventis; and Neulasta, an immunostimulants from Amgen; have record sales of $5.6 billion, $4.3 billion and $3.4 billion respectively. Similarly, Epogen from Amgen, Avonex from Biogen Idec, Eprex from Johnson & Johnson and Rebif from Merck, which reported sales of over $2 billion in 2009, will lose patents by 2013.

Page 8: Dna of biopreneur

Affordable health care

• Service innovations: Eye care, Heart surgery, Tele medicine, remote monitoring of patients,

• Reverse innovations: from Innovators/ start-ups –Mosquito traps, infant warmers

• Non-profit design centers: http://www.d-rev.org/index.html

Page 9: Dna of biopreneur

Services needed

• Technology search, access, acquisition, negotiation

• Business plan• Regulatory approvals

Page 10: Dna of biopreneur

Biopreneur program

Opportunity

Consultancy